CD274 and neoplasm: Nevertheless, the FDA recently granted accelerated approval to atezolizumab in combination with nab-paclitaxel patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (PD-L1 IC ≥ 1% of the tumor area) [104].